CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD)’s share price shot up 12.9% on Monday . The stock traded as high as $9.90 and last traded at $9.71, with a volume of 77,316 shares changing hands. The stock had previously closed at $8.60.

Separately, Zacks Investment Research upgraded CoLucid Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, July 12th.

The stock has a 50 day moving average of $8.84 and a 200-day moving average of $7.23. The company’s market cap is $163.08 million.

CoLucid Pharmaceuticals (NASDAQ:CLCD) last released its earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.84) by $0.22. Analysts forecast that CoLucid Pharmaceuticals Inc. will post ($4.01) EPS for the current year.

In other news, major shareholder Domain Partners Vi, L.P. sold 153,028 shares of CoLucid Pharmaceuticals stock in a transaction that occurred on Wednesday, August 3rd. The shares were sold at an average price of $8.45, for a total transaction of $1,293,086.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

CoLucid Pharmaceuticals, Inc is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.